Patents by Inventor Daniel Maneval

Daniel Maneval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070259429
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: May 18, 2001
    Publication date: November 8, 2007
    Applicant: Canji,Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20070253932
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: March 9, 2007
    Publication date: November 1, 2007
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20070128166
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: October 23, 2006
    Publication date: June 7, 2007
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20070122379
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: November 29, 2006
    Publication date: May 31, 2007
    Applicant: Canji, Inc.
    Inventors: Loretta Nielsen, Jo Horowitz, Daniel Maneval, G. Demers, Mary Rybak, Gene Resnick
  • Publication number: 20070031381
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: September 16, 2005
    Publication date: February 8, 2007
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Kenneth Wills, Daniel Maneval
  • Publication number: 20070014768
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: July 25, 2006
    Publication date: January 18, 2007
    Applicant: Canji, Inc.
    Inventors: Loretta Nielson, Jo Horowitz, Daniel Maneval, G. Demers, Mary Rybak, Gene Resnick
  • Publication number: 20070009485
    Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
    Type: Application
    Filed: May 25, 2006
    Publication date: January 11, 2007
    Inventors: Susan Conroy, Engler Heidrun, Daniel Maneval
  • Publication number: 20070009486
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: June 14, 2006
    Publication date: January 11, 2007
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060275261
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: September 28, 2005
    Publication date: December 7, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060233759
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: December 14, 2005
    Publication date: October 19, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060171925
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: October 19, 2005
    Publication date: August 3, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060140910
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: December 27, 2005
    Publication date: June 29, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060099187
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: December 21, 2005
    Publication date: May 11, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060039893
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: August 10, 2005
    Publication date: February 23, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20060034804
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: May 16, 2005
    Publication date: February 16, 2006
    Applicant: Canji, Inc.
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20050142112
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: April 13, 2004
    Publication date: June 30, 2005
    Inventors: Loretta Nielsen, Jo Horowitz, Daniel Maneval, G. Demers
  • Publication number: 20050031590
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
    Type: Application
    Filed: May 18, 2001
    Publication date: February 10, 2005
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval
  • Publication number: 20050014259
    Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
    Type: Application
    Filed: August 6, 2004
    Publication date: January 20, 2005
    Inventors: Susan Conroy, Heidrun Engler, Daniel Maneval
  • Publication number: 20030091534
    Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.
    Type: Application
    Filed: May 18, 2001
    Publication date: May 15, 2003
    Inventors: Richard Gregory, Ken Wills, Daniel Maneval